Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta

Email Facebook Twitter

TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake
Exclusive: Hardman & Co Investor Forum - Severn Trent, Calculus Capital, Volta Finance, Residential

Member Info for biotechanalyst

Send a private message to biotechanalyst

Member Since: Tue, 30th Apr 2019

Number of Share Chat Posts (all time): 4
Number of Share Chat Posts (last 30 days): 3

Last Posted: 22 May '19

Post Distribution over the last 30 days

22 May '19

Evaluate has of couse provided an excellent write up on this deal, suggesting Nuevolution has its own TYk2 inhibitor programme as well. https://www.evaluate.com/vantage/articles/news/snippets/amgen-goes-nuevolution-not-revolution
22 May '19

Have now posted a slightly longer item on this on the QD website, also using correct spelling of Nuevolution! https://quoteddata.com/2019/05/amgen-takeover-nuevolution-rare-valuation-preclin-immuneinflam-assets/
22 May '19

Sareum investors might be interested to note the $160m valuation placed on Nuevelution (Swedish biotech, subject to a takeover announced today by Amgen), which has a pipeline with ~4 preclin assets (one partnered, see https://nuevolution.com/pipelines/programs/ ) for immune/inflam indications, all potentially adressable with a Tyk2 inhib.
30 Apr '19

Lilly appears to have discontinued prexasertib, the only competitor to SRA737. Potentially posistive for Sierra Oncology and Sareum.

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.